Page 4 - James Cutrell News Today

The omicron variant of the coronavirus makes up nearly 3% of COVID-19 cases in the US. The CDC has detected the new strain in 43 states. Latest news.

Omicron May Sideline Two Leading Drugs Against COVID-19.

Antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for early COVID-19

WASHINGTON — As strained U.S. hospitals brace for a new surge of COVID-19 cases caused by the fast-spreading omicron variant, doctors are warning of yet another challenge: the two standard

For more than a year antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for early COVID-19, thanks to their ability to head off severe disease and keep patients out of the hospital.

The rapidly-spreading omicron variant may soon leave U.S. doctors without two of the standard treatments they've used to fight COVID-19.

“I think there’s going to be a shortage,” said Dr. Jonathan Li, director of the Harvard/Brigham Virology Specialty Laboratory. “We’re down to one FDA-authorized monoclonal antibody” with omicron because of the reduced effectiveness of Regeneron and Lilly’s drugs.

The shrinking toolbox of treatments is a reminder that the virus still has the upper hand in the U.S.

The rapidly-spreading omicron variant may soon leave U.S. doctors without two of the standard treatments they've used to fight COVID-19.

As strained U.S. hospitals brace for a new surge of COVID-19 cases caused by the fast-spreading omicron variant, doctors are warning of yet another challenge: the two standard drugs theyve used to fight infections are unlikely to work against the new strain.